INT232413

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.49
First Reported 2007
Last Reported 2010
Negated 2
Speculated 0
Reported most in Body
Documents 9
Total Number 10
Disease Relevance 2.58
Pain Relevance 4.13

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Ifx (Mus musculus)
Pain Link Frequency Relevance Heat
Infliximab 461 100.00 Very High Very High Very High
rheumatoid arthritis 178 99.60 Very High Very High Very High
antagonist 167 98.84 Very High Very High Very High
Adalimumab 488 97.88 Very High Very High Very High
Etanercept 125 93.92 High High
corticosteroid 20 82.60 Quite High
withdrawal 3 63.16 Quite High
Arthritis 179 50.00 Quite Low
spinal inflammation 153 50.00 Quite Low
Rheumatism 13 47.84 Quite Low
Disease Link Frequency Relevance Heat
Cold Sores 178 100.00 Very High Very High Very High
Rheumatoid Arthritis 181 99.60 Very High Very High Very High
Disease 194 98.46 Very High Very High Very High
Infection 48 92.24 High High
Sprains And Strains 90 83.88 Quite High
Herpes Simplex Virus 2 80.08 Quite High
Low Back Pain 174 50.00 Quite Low
Seronegative Spondarthritis 164 50.00 Quite Low
Cancer 18 50.00 Quite Low
Necrosis 16 50.00 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
exon region of the highly efficient reactivator McKrae, but not in the poor reactivator, KOS clearly suggests that the chromatin remodeling that occurs in response to a reactivation stressor is a fundamental property associated with reactivation of HSV-1 rather than a consequence due to the nature of the stimulus or as a global response to epinephrine stimulation.
Positive_regulation (reactivation) of HSV-1 associated with cold sores
1) Confidence 0.49 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2973973 Disease Relevance 0.37 Pain Relevance 0
However, the exact mechanism of the LAT in reactivation of HSV-1 has yet to be elucidated.
Positive_regulation (reactivation) of HSV-1 associated with cold sores
2) Confidence 0.49 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2973973 Disease Relevance 1.08 Pain Relevance 0
Peyrin-Biroulet et al (2006) evaluated, in a 52-week open-label trial, the efficacy and safety of ADA maintenance therapy in 24 CD patients who lost response to IFX (as judged by the investigator despite an increase of IFX dosage or of dosage frequency).
Positive_regulation (increase) of IFX associated with infliximab, adalimumab and disease
3) Confidence 0.27 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727899 Disease Relevance 0.26 Pain Relevance 0.54
If this result was confirmed in larger studies, the cost-effectiveness of IFX would be indisputably increased in early RA.
Positive_regulation (increased) of IFX associated with infliximab and rheumatoid arthritis
4) Confidence 0.26 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376089 Disease Relevance 0.55 Pain Relevance 0.55
The low ACR50 and ACR70 and good EULAR response rates at Week 16 in patients with negative HACA appear to be more likely related to confounding baseline characteristics, such as a greater percentage of patients who had experienced no response to IFX and a longer RA duration compared with patients with positive HACA status.
Neg (no) Positive_regulation (response) of IFX associated with infliximab and rheumatoid arthritis
5) Confidence 0.22 Published 2008 Journal Clin Rheumatol Section Body Doc Link PMC2468311 Disease Relevance 0.15 Pain Relevance 0.47
All three subgroups experienced improvements from baseline in both TJC and SJC at all time points measured, with those who reported intolerance to IFX or loss of response achieving a slightly greater benefit compared with those who had no response to IFX (Table 3).
Neg (no) Positive_regulation (response) of IFX associated with infliximab
6) Confidence 0.20 Published 2008 Journal Clin Rheumatol Section Body Doc Link PMC2468311 Disease Relevance 0.05 Pain Relevance 0.21
The DAS28 and the HAQ DI improved from baseline in all three subgroups at all time points evaluated, with the greatest response occurring in those patients who had stopped IFX owing to loss of response (Week 16 data shown in Table 3).
Positive_regulation (stopped) of IFX associated with infliximab
7) Confidence 0.20 Published 2008 Journal Clin Rheumatol Section Body Doc Link PMC2468311 Disease Relevance 0.06 Pain Relevance 0.32
Patients who had initially responded to prior IFX and discontinued IFX because of loss of response (perhaps caused by antibodies against IFX) or because of intolerance experienced much greater BASDAI 50 and ASAS40 response rates than did patients who discontinued IFX after lack of initial response.
Positive_regulation (discontinued) of IFX associated with infliximab
8) Confidence 0.06 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911911 Disease Relevance 0 Pain Relevance 0.68
Patients who had initially responded to prior IFX and discontinued IFX because of loss of response (perhaps caused by antibodies against IFX) or because of intolerance experienced much greater BASDAI 50 and ASAS40 response rates than did patients who discontinued IFX after lack of initial response.
Positive_regulation (responded) of IFX associated with infliximab
9) Confidence 0.06 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911911 Disease Relevance 0 Pain Relevance 0.66
Patients who had initially responded to prior IFX and discontinued IFX because of loss of response (perhaps caused by antibodies against IFX) or because of intolerance experienced much greater BASDAI 50 and ASAS40 response rates than did patients who discontinued IFX after lack of initial response.
Positive_regulation (discontinued) of IFX associated with infliximab
10) Confidence 0.06 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911911 Disease Relevance 0.05 Pain Relevance 0.71

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox